Get the Stockscreener App
89.76
2.62%
2.29
After Hours:
89.28
-0.48
-0.53%
Zimmer Biomet Holdings Inc stock is traded at $89.76, with a volume of 2.41M.
It is up +2.62% in the last 24 hours and up +2.78% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$87.47
Open:
$87.47
24h Volume:
2.41M
Relative Volume:
1.02
Market Cap:
$17.37B
Revenue:
$8.41B
Net Income/Loss:
$760.80M
P/E Ratio:
23.31
EPS:
3.8513
Net Cash Flow:
$1.05B
1W Performance:
-1.62%
1M Performance:
+2.78%
6M Performance:
-5.27%
1Y Performance:
-4.17%
1-Day Range:
$86.81
$90.75
1-Week Range:
$83.72
$90.75
52-Week Range:
$79.12
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
89.76 | 16.66B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
95.63 | 158.05B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
324.73 | 120.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.06 | 100.14B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.60 | 63.44B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
95.18 | 52.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-20-26 | Initiated | William Blair | Mkt Perform |
| Jan-09-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India - Reuters
Enterprise value to EBIT forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH - TradingView
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity - Yahoo Finance
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
‘Cool move’ by Zimmer part of med-tech’s tuck-in deals trend - BioWorld News
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
Persona IQ from Zimmer Biometsmart knee implant brings continuous data to US surgeons - AD HOC NEWS
A Look at Zimmer Biomet Holdings Inc (ZBH) After 5.6% Decline -- GF Value $126.11 vs Price $86.09 - GuruFocus
Zimmer Biomet Holdings, Inc.'s Stock Price Plummets to $86.09, Suffers a Sharp 5.64% Drop - Smartkarma
Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors - MSN
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Why is Zimmer Biomet stock sliding today? By Investing.com - Investing.com Canada
What is behind Zimmer Biomet stock's recent drop in value today - Traders Union
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
Pacira BioSciences to Divest iovera° to Zimmer Biomet for Up to $140 Million - Quiver Quantitative
Pacira (NASDAQ: PCRX) divests iovera° business to Zimmer Biomet for up to $140M - Stock Titan
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
Zimmer Biomet secures $2.75 billion credit, shares under Wall Street scrutiny - AD HOC NEWS
Zimmer Biomet Holdings (ZBH) Secures New Credit Agreements to Bo - GuruFocus
The Persona Knee System from Zimmer Biomet Holdings Inc.modular design tailored to each joint - AD HOC NEWS
Is Zimmer Biomet stock underperforming the S&P 500? - MSN
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zimmer Biomet Expands Liquidity With New Credit Facilities - TipRanks
Zimmer Biomet Refinances With New $1.5B Five-Year and $1.25B 364-Day Facilities; 2025 Lines Ended - TradingView
Zimmer Biomet (ZBH) secures new five-year and 364-day credit lines - Stock Titan
Price to sales forward of Zimmer Biomet Holdings, Inc. – SWB:ZIM - TradingView
Price to earnings forward of Zimmer Biomet Holdings, Inc. – SWB:ZIM - TradingView
Zimmer Biomet adjusts earnings guidance, shares anchored in NYSE medtech peer group - AD HOC NEWS
The ROSA Knee System from Zimmer Biomet Holdings Inc.robotic guidance aims at more consistent kne - AD HOC NEWS
Zimmer Biomet refines orthopedic focus, shares steady on NYSE - AD HOC NEWS
The Taperloc Complete Hip System from Zimmer Biomet Holdingsstem design built on Legacy for consi - Ad-hoc-news.de
Is Zimmer Biomet Holdings (ZBH) Undervalued After Raising Earnings Guidance? - Sahm
Zimmer Biomet Holdings, Inc. Actuals & Estimates (NYSE:ZBH) - TradingView
Zimmer Biomet Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Zimmer Biomet Holdings, Inc. Actuals & Estimates (BX:ZIM) - TradingView
Zimmer Biomet (NYSE:ZBH) Sparks A Value Debate - Kalkine Media
Zimmer Biomet lifts earnings guidance, shares trade near key technical levels - Ad-hoc-news.de
Zimmer Biomet Holdings, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.25 Sh - TradingView
TD Cowen Maintains Zimmer Biomet Holdings(ZBH.US) With Buy Rating, Maintains Target Price $109 - Moomoo
The Persona IQ Knee from Zimmer Biomet Holdings Inc.smart implant data for everyday mobility - Ad-hoc-news.de
ZIM Forecast — Price Target — Prediction for 2027 - TradingView
Zimmer Biomet with clear technical picture, shares between support and resistance - Ad-hoc-news.de
Zimmer Biomet Holdings, Inc.: - marketscreener.com
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Form 144 ZIMMER BIOMET HOLDINGS For: 24 June By Investing.com - Investing.com Nigeria
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zimmer Biomet Holdings Inc Stock (ZBH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yi Sang | Group President, Asia Pacific |
May 29 '26 |
Sale |
82.64 |
5,000 |
413,216 |
27,251 |
2.25%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):